3 Kansas City Health Systems Partner to Launch Precision Medicine Platform

The University of Kansas Health System, KU Medical Center, and Children's Mercy collaborate on theranostics platform for adult and pediatric patients.

Published on Feb. 19, 2026

Got story updates? Submit your updates here. ›

Three major healthcare systems in the Kansas City region - the University of Kansas Health System, the University of Kansas Medical Center, and Children's Mercy - are partnering to establish the nation's first fully integrated theranostics platform for both adult and pediatric patients. Theranostics is a precision medicine approach that uses radiopharmaceuticals to diagnose and treat disease.

Why it matters

This collaboration represents a significant advancement in precision medicine, as theranostics has traditionally been used almost exclusively in adult care. By bringing together these three leading healthcare organizations, the new platform will drive innovation and investment in the Kansas City region as a destination for cutting-edge healthcare and medical research.

The details

The vertically integrated theranostic approach will allow for radiopharmaceutical production, molecular imaging, radiopharmaceutical therapy, and radioligand clinical trials to all take place in the same location. The three health systems are partnering with Bold Advanced Medical Future Health, a platform for molecular imaging and radiopharmaceutical therapy, to create the new precision medicine platform.

  • The partnership was announced on February 17, 2026.

The players

University of Kansas Health System

A major healthcare system based in Kansas City, Kansas.

University of Kansas Medical Center

A medical research and education institution located in Kansas City, Kansas.

Children's Mercy

A pediatric healthcare system based in Kansas City, Missouri.

Bold Advanced Medical Future Health

A platform for molecular imaging and radiopharmaceutical therapy that is partnering with the three health systems.

Bob Page

President and CEO of the University of Kansas Health System.

Got photos? Submit your photos here. ›

What they’re saying

“Theranostics is the next forefront of precision medical care and research. This collaboration will advance both discovery and treatment, while driving investment in the Kansas City region as a destination for healthcare and research.”

— Bob Page, President and CEO, University of Kansas Health System (University of Kansas Health System news release)

What’s next

The three health systems and Bold Advanced Medical Future Health will work to establish the new vertically integrated theranostics platform, which will include radiopharmaceutical production, molecular imaging, radiopharmaceutical therapy, and radioligand clinical trials.

The takeaway

This groundbreaking partnership positions the Kansas City region as a national leader in precision medicine, particularly in the emerging field of theranostics. By bringing together these three prominent healthcare organizations, the new platform will drive innovation, investment, and access to cutting-edge treatments for both adult and pediatric patients.